Vitrolife AB (VITR)
Stockholm Exchange · Sweden · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 97.80 |
|---|---|
| 52-week range | 83.74 – 151.94 |
| Return, 1 month / 3 months | +6.9% / +10.6% |
| Return, 1 year / 3 years | −27.6% / −28.7% |
| Trend | Uptrend |
| RSI (14) | 58 |
| Volatility (1 year) | 42.2% |
| Worst drawdown (1 year) | -43.3% |
| Average daily value traded | 20.33M SEK |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Vitrolife is a Swedish medical technology company based in Gothenburg that focuses on assisted reproduction. It develops and supplies culture media, solutions and laboratory equipment used by fertility clinics and hospital laboratories to handle eggs, sperm and embryos during treatment. Its products include media for embryo culture, freezing and storage systems, and instruments for working with reproductive cells. Customers are mainly clinics and laboratories that provide fertility care in many countries.
The shares are listed on the Stockholm Exchange in Sweden under the code VITR, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Vitrolife AB (VITR) trades on the Stockholm Exchange in Sweden. It last closed at SEK 97.80 on 19 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 413 of 911 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 27.6% and over the last three months it rose 10.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 0.4% | ||
| From 52-week high | -34.6% | ||
| Momentum | 50 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 10.6% | ||
| 6-month return | -10.3% | ||
| 12-month return, skipping the last month | -32.2% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 42.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -43.3% | ||
| Liquidity | 85 · Strong | Trades actively. | |
| Average daily value traded | 20.33M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.7% |
|---|---|
| 1 month | +6.9% |
| 3 months | +10.6% |
| 6 months | −10.3% |
| 1 year | −27.6% |
| 3 years | −28.7% |
| 5 years | – |
Signals
| 50-day / 200-day average | 93.27 / 97.37 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.85 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 May 2026 | SEK 1.1000 |
| 30 Apr 2025 | SEK 1.1000 |
| 26 Apr 2024 | SEK 1.0000 |
| 28 Apr 2023 | SEK 0.8500 |
| 28 Apr 2022 | SEK 0.8000 |
| 29 Apr 2021 | SEK 0.8000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.